594 related articles for article (PubMed ID: 16971522)
1. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
Cui M; Honore P; Zhong C; Gauvin D; Mikusa J; Hernandez G; Chandran P; Gomtsyan A; Brown B; Bayburt EK; Marsh K; Bianchi B; McDonald H; Niforatos W; Neelands TR; Moreland RB; Decker MW; Lee CH; Sullivan JP; Faltynek CR
J Neurosci; 2006 Sep; 26(37):9385-93. PubMed ID: 16971522
[TBL] [Abstract][Full Text] [Related]
2. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
[TBL] [Abstract][Full Text] [Related]
3. Additive antinociceptive effects of the selective Nav1.8 blocker A-803467 and selective TRPV1 antagonists in rat inflammatory and neuropathic pain models.
Joshi SK; Honore P; Hernandez G; Schmidt R; Gomtsyan A; Scanio M; Kort M; Jarvis MF
J Pain; 2009 Mar; 10(3):306-15. PubMed ID: 19070548
[TBL] [Abstract][Full Text] [Related]
4. Differential involvement of TRPV1 receptors at the central and peripheral nerves in CFA-induced mechanical and thermal hyperalgesia.
Kanai Y; Hara T; Imai A; Sakakibara A
J Pharm Pharmacol; 2007 May; 59(5):733-8. PubMed ID: 17524240
[TBL] [Abstract][Full Text] [Related]
5. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
6. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of (3S)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (JTS-653), a novel transient receptor potential vanilloid 1 antagonist.
Kitagawa Y; Miyai A; Usui K; Hamada Y; Deai K; Wada M; Koga Y; Sakata M; Hayashi M; Tominaga M; Matsushita M
J Pharmacol Exp Ther; 2012 Aug; 342(2):520-8. PubMed ID: 22588258
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
Brown BS; Keddy R; Zheng GZ; Schmidt RG; Koenig JR; McDonald HA; Bianchi BR; Honore P; Jarvis MF; Surowy CS; Polakowski JS; Marsh KC; Faltynek CR; Lee CH
Bioorg Med Chem; 2008 Sep; 16(18):8516-25. PubMed ID: 18722778
[TBL] [Abstract][Full Text] [Related]
9. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
[TBL] [Abstract][Full Text] [Related]
10. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
Gomtsyan A; Bayburt EK; Schmidt RG; Surowy CS; Honore P; Marsh KC; Hannick SM; McDonald HA; Wetter JM; Sullivan JP; Jarvis MF; Faltynek CR; Lee CH
J Med Chem; 2008 Feb; 51(3):392-5. PubMed ID: 18183945
[TBL] [Abstract][Full Text] [Related]
11. Involvement of TRPV1 in nociceptive behavior in a rat model of cancer pain.
Shinoda M; Ogino A; Ozaki N; Urano H; Hironaka K; Yasui M; Sugiura Y
J Pain; 2008 Aug; 9(8):687-99. PubMed ID: 18455478
[TBL] [Abstract][Full Text] [Related]
12. KChIP3 N-Terminal 31-50 Fragment Mediates Its Association with TRPV1 and Alleviates Inflammatory Hyperalgesia in Rats.
Tian NX; Xu Y; Yang JY; Li L; Sun XH; Wang Y; Zhang Y
J Neurosci; 2018 Feb; 38(7):1756-1773. PubMed ID: 29335353
[TBL] [Abstract][Full Text] [Related]
13. 7-tert-Butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, a classic polymodal inhibitor of transient receptor potential vanilloid type 1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity.
Nash MS; McIntyre P; Groarke A; Lilley E; Culshaw A; Hallett A; Panesar M; Fox A; Bevan S
J Pharmacol Exp Ther; 2012 Aug; 342(2):389-98. PubMed ID: 22566669
[TBL] [Abstract][Full Text] [Related]
14. Systemic and site-specific effects of A-425619, a selective TRPV1 receptor antagonist, on wide dynamic range neurons in CFA-treated and uninjured rats.
McGaraughty S; Chu KL; Faltynek CR; Jarvis MF
J Neurophysiol; 2006 Jan; 95(1):18-25. PubMed ID: 16162831
[TBL] [Abstract][Full Text] [Related]
15. RNA interference-mediated knock-down of transient receptor potential vanilloid 1 prevents forepaw inflammatory hyperalgesia in rat.
Kasama S; Kawakubo M; Suzuki T; Nishizawa T; Ishida A; Nakayama J
Eur J Neurosci; 2007 May; 25(10):2956-63. PubMed ID: 17509082
[TBL] [Abstract][Full Text] [Related]
16. Acute inflammation sensitizes knee-innervating sensory neurons and decreases mouse digging behavior in a TRPV1-dependent manner.
Chakrabarti S; Pattison LA; Singhal K; Hockley JRF; Callejo G; Smith ESJ
Neuropharmacology; 2018 Dec; 143():49-62. PubMed ID: 30240782
[TBL] [Abstract][Full Text] [Related]
17. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
Ognyanov VI; Balan C; Bannon AW; Bo Y; Dominguez C; Fotsch C; Gore VK; Klionsky L; Ma VV; Qian YX; Tamir R; Wang X; Xi N; Xu S; Zhu D; Gavva NR; Treanor JJ; Norman MH
J Med Chem; 2006 Jun; 49(12):3719-42. PubMed ID: 16759115
[TBL] [Abstract][Full Text] [Related]
18. Eriodictyol: a flavonoid antagonist of the TRPV1 receptor with antioxidant activity.
Rossato MF; Trevisan G; Walker CI; Klafke JZ; de Oliveira AP; Villarinho JG; Zanon RB; Royes LF; Athayde ML; Gomez MV; Ferreira J
Biochem Pharmacol; 2011 Feb; 81(4):544-51. PubMed ID: 21087598
[TBL] [Abstract][Full Text] [Related]
19. AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties.
Gavva NR; Tamir R; Qu Y; Klionsky L; Zhang TJ; Immke D; Wang J; Zhu D; Vanderah TW; Porreca F; Doherty EM; Norman MH; Wild KD; Bannon AW; Louis JC; Treanor JJ
J Pharmacol Exp Ther; 2005 Apr; 313(1):474-84. PubMed ID: 15615864
[TBL] [Abstract][Full Text] [Related]
20. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.
Gunthorpe MJ; Hannan SL; Smart D; Jerman JC; Arpino S; Smith GD; Brough S; Wright J; Egerton J; Lappin SC; Holland VA; Winborn K; Thompson M; Rami HK; Randall A; Davis JB
J Pharmacol Exp Ther; 2007 Jun; 321(3):1183-92. PubMed ID: 17392405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
